Arrowstreet Capital
CBAY

Arrowstreet Capital’s Cymabay Therapeutics CBAY Stock Holding History

Arrowstreet Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,515
Closed -$296K – 1802
2023
Q4 		$296K Sell
12,515
-615,788
-98% -$11M ﹤0.01% 1304
2023
Q3 		$9.37M Buy
+628,303
New +$8.33M 0.01% 531
2020
Q3 		– Sell
-1,036,294
Closed -$3.62M – 2577
2020
Q2 		$3.62M Buy
+1,036,294
New +$2.99M 0.01% 1203
2020
Q1 		– Sell
-18,425
Closed -$36K – 2180
2019
Q4 		$36K Buy
+18,425
New +$69.2K ﹤0.01% 1693

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Arrowstreet Capital's CBAY Position: Q1 2024 in Review

Arrowstreet Capital sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 12,515 shares — an estimated $296K sold.

Arrowstreet Capital first reported a position in CBAY in Q4 2019 and held it in 4 quarters. The position peaked at $9.37M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Arrowstreet Capital reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Arrowstreet Capital sold 12,515 Cymabay Therapeutics shares in Q1 2024, an estimated $296K.
  • Arrowstreet Capital first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 4 quarters.
  • Arrowstreet Capital's Cymabay Therapeutics position peaked at $9.37M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Arrowstreet Capital's 13F filing for Q1 2024, filed 15 May 2024.